Abstract library

267 results for "special types".
#1592 Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Approach to the Special Type of Breast Malignancy
Introduction: WHO classification from 2003 defines primary neuroendocrine carcinomas (NEC) of the breast as a group of tumors with expression of neuroendocrine markers in more than 50% of tumor cells. In the current WHO classification this category is renamed to “carcinomas with neuroendocrine features” without defined clear-cut of the percentage of tumor cells positive for neuroendocrine markers.
Conference: 14th Annual ENETS conference (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Alma Demirović
#36 A monocentric analysis of patients with pulmonary neuroendocrine tumors over 15 years: long term survival and life quality dependent from histological subtypes and surgical management
Introduction: Pulmonary neuroendocrine tumors substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized interdisciplinary centers, a broad therapeutical armentarium can be used to achieve optimal treatment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Johannes N Hoffmann
Authors: Zahn S, Hornung H, Schick K S, Winter H, ...
#689 Immunohistochemical Expression of Somatostatin Receptors 1, 2, 3, and 5 Types (SSR) in Functioning and Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors
Introduction: SSRs are therapeutic targets for the somatostatin analogues in treatment of gasrtroenteropancreatic neuroendocrine tumors (GEP-NET).
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: MD Larisa Gurevich
#1293 The Role of Hepatic Intra-arterial Therapies in Metastatic Neuroendocrine Tumours (NETs): A Specialist Center Experience.
Introduction: Liver metastases are relatively common in patients with NETs, having a negative impact on prognosis. The options for selective liver metastases therapy are limited to catheter guided procedures: TACE, TAE or SIRT. Data regarding the effectiveness & safety of these procedures in different types of NETs is limited.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: MD Simona Glasberg
#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#1423 Multidisciplinary Management and Patient Flow in Neuroendocrine Tumors (NET): Consensus of a Tertiary Hospital
Introduction: Currently, there has been an improvement in diagnostic procedures and treatments of NET. Therefore, an effective teamwork is needed to choose the best approach for patients.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Paula Jimenez-Fonseca
#184 Somatostatin Analogues as a Therapeutic Option in a Series of 91 Patients with Gastric Carcinoids
Introduction: Gastric carcinoid tumors (GC) represent about 10-30% of carcinoid tumors and about 1% of all stomach neoplasms. They include three types : type 1 (70-85%), type 2 (5-10%) and type 3 (15-25%).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Christos St. Basagiannis
#544 Second Primary Tumor in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): Data From a Retrospective Observational Unicentric Study
Introduction: It is known that GEPNETs are associated with a high incidence of second primary tumors, especially in the context of inherited syndromes and synchronous injuries to the intestine.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Paula J Fonseca
#614 The Effect of Patient and Doctors Delay in Patients with Neuroendocrine Tumors
Introduction: The diagnosis of neuroendocrine tumors (NET) is often delayed due to the vague symptoms and rareness of the disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Catharina M Korse
#1197 The Neuron-Specific Enolase Assessment in Patients with Neuroendocrine Tumors with or without Carcinoid Syndrome
Introduction: NeuroEndocrine Tumors (NETs) comprises a wide area of clinical presentations and neuroendocrine markers.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD Mara Carsote